Jaguar Entered into a Licence Agreement with SynWorld to Commercialise Canalevia in China to Treat Diarrhea in Dogs
Shots:
- Jaguar to receive $5M monthly license fee payments along with a quarterly purchase of its common stock by SynWorld priced at $5M & an additional monthly service fee of ~$5M in unregistered Jaguar stock during the initial 2yrs. term of the agreement. SynWorld is responsible to obtain regulatory approval and commercialize the product following approval in China
- Under the terms of the agreement, Jaguar will receive 60% of any profits from sales of Canalevia whereas, the profit-sharing will become 80% if Jaguar reimburses SynWorld for the expenses of obtaining regulatory approval in China
- Canalevia (oral) is a plant-based extraction & purification of red bark sap used to treat CID in dogs. Canalevia has been approved by the US FDA in Dec’21 for the same indication
Ref: Accesswire | Image: Jaguar Health
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
